IADR and GlaxoSmithKline Consumer Healthcare announ... ( Alexandria Va. The International As...)

IADR and GlaxoSmithKline Consumer Healthcare announce winners

Date:5/15/2008

Alexandria, Va. The International Association for Dental Research (IADR) and GlaxoSmithKline (GSK) Consumer Healthcare today announced the 2008 winners of the annual IADR/GSK Innovation in Oral Care Awards. The three prestigious awards recognize research in innovative oral care technologies that may maintain and improve oral health and the quality of life.

Sharing the $225,000 unrestricted research grant, which is funded by GSK Consumer Healthcare and administered by the IADR, are:

Urban Hagg, D.D.S., The Prince Philip Dental Hospital, University of Hong Kong, China, and co-investigators Ricky Wong, Lakshman Samaranayake, Richard Kao, and Michelle Yuen for A Natural Edible Agent for Reduction of Oral Biofilm. This research study will look at Prunus mume, a common fruit in Asia, and its effectiveness in inhibiting bacteria commonly found in oral biofilm. If shown to be effective, Prunus mume will be accepted as a natural oral biofilm-reducing agent, which would ultimately help in the prevention of dental caries and periodontal disease.
Keith Kirkwood, D.D.S., Ph.D., Microbiology and Immunology, Medical University of South Carolina, for Targeting Post-transcriptional Signaling for Periodontitis. This research study will explore the role of posttranscriptional cytokine regulation in periodontal inflammation and bone loss, which may yield new possibilities for the treatment of periodontal diseases and other chronic inflammatory diseases.
David T.W. Wong, D.M.D., D.M.Sc., University of California at Los Angeles (UCLA), School of Dentistry, and coinvestigators Wei Lao and Fang Wei for SPITDX: A Universal Platform for Salivary Biomarker Detection. This research project aims to develop a universal platform, where salivary biomarkers associated with disease phenotypes can be rapidly detected in under five minutes. This platform will allow scientific results to be transferred faster, allowing patients who su
'/>"/>

Contact: Denise Streszoff
dstreszoff@iadr.org
703-299-8087
International & American Association for Dental Research
Source:Eurekalert

0

GOOD

Page: 1 2 3
Related medicine news :

1. A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence
2. Concern From Doctors Regarding the Cardiovascular Safety of GlaxoSmithKlines Avandia Increases Nine-Fold Following Publication of Meta-Analysis
3. GlaxoSmithKline Confirms Receipt of FDA Letter on Regulatory Reporting
4. Astellas/GlaxoSmithKlines Vesicare Has Advantages Over Pfizers Detrol LA/Detrusitol XL in Reducing Episodes of Urge Urinary Incontinence
5. GlaxoSmithKline Awards Eight Area Healthcare Nonprofits with $40,000 Each in Funding
6. EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
7. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
8. AUDIO from Medialink and GlaxoSmithKline: Get Ready to Get Moving to a New You in the New Year
9. Audio from Medialink and GlaxoSmithKline: Cleaning House ... Overhaul Your Fridge and Pantry to Lose Weight
10. VIDEO from Medialink and GlaxoSmithKline: Really Think You Can Lose 30 Pounds in 30 Days?
11. AUDIO from Medialink and GlaxoSmithKline: Setting Realistic Goals for a New You in the New Year

Post Your Comments:

(Date:11/27/2009)...ov.27/PRNewswire-FirstCall/--TheGymboreeCorporatio...willpresentattheNASDAQOMX23rdInvestorProgram,which...esday,December2,2009,at11:45a.m.GMT. ,, Toliste...ationovertheInternet,pleaselogontowww.gymboree.com...storandMediaRelations"andthen"ConferenceCalls&...

(Date:11/27/2009)...INE,France,Nov.27/PRNewswire/--TeamGarmin-Slipstre...dtoethicalsportinganddevelopingthenextgenerationof...mGarmin-TransitionswiththeadditionofTransitionsOpt...world,sleadingmanufacturerofadaptiveeyewear,offeri...selectionofspectaclelensessuchasTransitionslensesa...

(Date:11/27/2009)... XenaCare Holdings has announced that it has be...n, one of the largest nonprofit organizations dedi...ation. , Delray Beach, FL...nc. (OTCBB: XCHO), a company specializing in the m...hcare products, has announced today that is has be...

(Date:11/27/2009)... unprecedented medical, economic burdens, study pr...ws) -- The number of people with diabetes in the U...5 years, a new study predicts. , That would bri...with the disease, up from 23.7 million today. , ,...th diabetes will triple, the study also warns, ris...

(Date:11/27/2009)... Voyant Health™ announced today that Spec...its TraumaCad Enterprise orthopedic templating sol... , (PRWEB) November 27, 20...ectrum Health (Grand Rapids, Michigan) has license...olution and its TraumaCad Extend workflow solution...

Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2 Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3 Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4 Health News:Diabetes Cases Expected to Double in 25 Years 2 Health News:Diabetes Cases Expected to Double in 25 Years 3 Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2 Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3

[0] The Gymboree Corporation to Present at NASDAQ OMX 23rd Investor Program [0] Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor [0] XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation [0] Diabetes Cases Expected to Double in 25 Years [0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend

..., May 7 Conseco, Inc. (NYSE: CNO ),today reporte...t a new quarterly sales record with an increase of...ieur said. "This performance included,an 11% incre...surance Group,s sales declined 21%, but specified ...

...is common in the aggressive form of the disease, r...althDay News) -- For the first time, a gene linked... has been identified, researchers report. , "This ...ldhood Cancer Research at The Children,s Hospital ...

...ON, May 7 -- Shire plc(LSE: SHP, Nasdaq: SHPGY), ...esented today at a major scientific meeting findin...NIV, a selective alpha-2A-agonist. This compound,...(ADHD)., The data demonstrated that INTUNIV showed...

...ct Examination Finds Serious Violations in Long-Te... Acting Insurance,Commissioner Joel Ario today ann...ich was necessary due to a pattern of consumer har...2.3 million fine and an additional $30,million in ...

....3 million fine, CARMEL, Ind., May 7 Conseco, In...g state insurance regulators and two of,its insura...(CSHI) Company,and Bankers Life and Casualty Compa...e claims practices and,procedures, complaint handl...

...y 7 Longer life expectancy, greater,interest in s...ccess are,all factors fueling growth in sales of o...ted $68.4 billion in 2007 sales, with a 3.9% CAGR ... BTC and Other Growth Trends, this market should e...

Conseco Reports First Quarter Results Gene Variation Linked to Neuroblastoma, a Childhood Cancer Shire investigational nonstimulant INTUNIV showed significant efficacy in reducing ADHD symptoms Insurance Department Fines Conseco Under Pennsylvania-Led, Multi-State Agreement Conseco Reaches Settlement of Multistate Market Conduct Examination Self-Medication One of Many Factors Driving OTC Drug Market Past $80 Billion by 2012

(Date:11/26/2009)...hAfrica,Nov.26/PRNewswire/--The2009Frost&Sulli...rmaceuticalMarketispresentedtoCiplaMedproSouthAfri...-bin/prnh/20081117/FSLOGO ) ,, FortheCompanyoft...kCiplaMedpro,sperformanceagainstkeycompetitors:gro...usinessprocesses,productsand/ortechnologiesandlead...

(Date:11/25/2009)....25/PRNewswire-FirstCall/--AmericanScientificResou...announcethattheyhaveopenedaregionalmarketingandpro...hasbeenabletosecurealocationabroad,providinganesse...tandfuturehealthandsafetyproductsforchildrenandadu...anyhousesinventoryinthestateofOhiowheretheywillals...

(Date:11/25/2009)....25/PRNewswire-FirstCall/--Hologic,Inc.(Hologicort...cturerandsupplierofpremiumdiagnostics,medicalimagi...ealthcareneedsofwomen,isusingtheannualmeetingofthe...PlaceinChicago,November29throughDecember3,2009tohi...osticmammographyworkstationsoftware. ,, TheHolo...

[0] Frost & Sullivan Award Underlines Cipla Medpro's Status as Company of the Year in the South African Generic Pharmaceutical Market [0] American Scientific Resources Inc. Opens Shanghai Location [0] New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity

...of patients with multiple sclerosis, remained re...l FTY720,- New data demonstrate 89% of patients fr...used by MS - three years after starting treatment,...disability, affects 2.5 million people wo...latory filings planned before end of 2009 in US an...

...tes potential for once daily oral d...neration MEK inhibitor, RDEA436, to enter Phase 1 ...2008 -, SAN DIEGO, April 15 Ardea Biosciences, I... presented demonstrating the,potent activity and f...mitogen-activated ERK kinase (MEK) inhibitor famil...

Other Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5 FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 2 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 3 Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors 4

FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors

...ic protein produced and stored in somatotrophs in ...the pituitary into the bloodstream in a pulsatile ...c somatostatin (SS) and GH-releasing factor (GHRF)...rs to be regulated by somatostatin, while the ampl...

...ocorticoid produced by the human adrenal cortex. I...y to corticosteroid-binding globulin (CBG), with t...ts on specific intracellular receptors with effect...e function, glucose counter-regulation, vascular t...

...F-I or somatomedin C) is a 7.6 kDa peptide produce...gen of cellular proliferation, exerting its action...n the circulation, IGF-I is bound to IGF-binding p...ions of IGF-I by modulating the interaction of IGF...

Medicine Products:

Bioactive hGH ELISA Test Cortisol RIA Test IGF-I IRMA Test (With Extraction)IGF-I IRMA Test (Non-Extraction)

IADR and GlaxoSmithKline Consumer Healthcare announ...( Alexandria Va. The International As...),Health